Literature DB >> 8684484

Increased bone formation in osteocalcin-deficient mice.

P Ducy1, C Desbois, B Boyce, G Pinero, B Story, C Dunstan, E Smith, J Bonadio, S Goldstein, C Gundberg, A Bradley, G Karsenty.   

Abstract

Vertebrates constantly remodel bone. The resorption of preexisting bone by osteoclasts and the formation of new bone by osteoblasts is strictly coordinated to maintain bone mass within defined limits. A few molecular determinants of bone remodelling that affect osteoclast activity have been characterized, but the molecular determinants of osteoblast activity are unknown. To investigate the role of osteocalcin, the most abundant osteoblast-specific non-collagenous protein, we have generated osteocalcin-deficient mice. These mice develop a phenotype marked by higher bone mass and bones of improved functional quality. Histomorphometric studies done before and after ovariectomy showed that the absence of osteocalcin leads to an increase in bone formation without impairing bone resorption. To our knowledge, this study provides the first evidence that osteocalcin is a determinant of bone formation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8684484     DOI: 10.1038/382448a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  353 in total

1.  Identification of two novel transmembrane gamma-carboxyglutamic acid proteins expressed broadly in fetal and adult tissues.

Authors:  J D Kulman; J E Harris; L Xie; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

Review 2.  Genetics of osteoporosis.

Authors:  S H Ralston
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

3.  Distinctive expression of extracellular matrix molecules at mRNA and protein levels during formation of cellular and acellular cementum in the rat.

Authors:  Y Sasano; Y Maruya; H Sato; J X Zhu; I Takahashi; I Mizoguchi; M Kagayama
Journal:  Histochem J       Date:  2001-02

4.  A TWIST in the fate of human osteoblasts identifies signaling molecules involved in skull development.

Authors:  E W Jabs
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

5.  Characterization of PHEX endopeptidase catalytic activity: identification of parathyroid-hormone-related peptide107-139 as a substrate and osteocalcin, PPi and phosphate as inhibitors.

Authors:  G Boileau; H S Tenenhouse; L Desgroseillers; P Crine
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

Review 6.  Vascular calcification and its relation to bone calcification: possible underlying mechanisms.

Authors:  Nilam Mody; Yin Tintut; Kristen Radcliff; Linda L Demer
Journal:  J Nucl Cardiol       Date:  2003 Mar-Apr       Impact factor: 5.952

7.  In vitro mineralization by preosteoblasts in poly(DL-lactide-co-glycolide) inverse opal scaffolds reinforced with hydroxyapatite nanoparticles.

Authors:  Sung-Wook Choi; Yu Zhang; Stavros Thomopoulos; Younan Xia
Journal:  Langmuir       Date:  2010-07-20       Impact factor: 3.882

8.  p53 and MDM2 are involved in the regulation of osteocalcin gene expression.

Authors:  Hankui Chen; Kevin Kolman; Natalie Lanciloti; Michael Nerney; Emily Hays; Chet Robson; Nalini Chandar
Journal:  Exp Cell Res       Date:  2012-03-03       Impact factor: 3.905

9.  Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study.

Authors:  Masataka Shiraki; Akira Itabashi
Journal:  J Bone Miner Metab       Date:  2009-01-27       Impact factor: 2.626

10.  Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism.

Authors:  Tara C Brennan-Speranza; Holger Henneicke; Sylvia J Gasparini; Katharina I Blankenstein; Uta Heinevetter; Victoria C Cogger; Dmitri Svistounov; Yaqing Zhang; Gregory J Cooney; Frank Buttgereit; Colin R Dunstan; Caren Gundberg; Hong Zhou; Markus J Seibel
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.